Overview

Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer

Status:
Terminated

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the safety and efficacy of combining abiraterone (with prednisone) with cabozantinib in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).

Phase:

Phase 2

Details

Lead Sponsor:

Exelixis

Treatments:

Abiraterone Acetate
Prednisone